Sime Armoyan Sells 10,900 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 10,900 shares of Knight Therapeutics stock in a transaction on Thursday, April 11th. The stock was sold at an average price of C$5.95, for a total transaction of C$64,855.00.

Sime Armoyan also recently made the following trade(s):

• On Monday, April 1st, Sime Armoyan bought 6,200 shares of Knight Therapeutics stock. The shares were acquired at an average cost of C$5.25 per share, with a total value of C$32,550.00.
• On Monday, March 25th, Sime Armoyan bought 351,000 shares of Knight Therapeutics stock. The shares were acquired at an average cost of C$5.25 per share, with a total value of C$1,842,750.00.
• On Monday, January 22nd, Sime Armoyan sold 28,200 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.75, for a total transaction of C$162,150.00.
• On Friday, January 19th, Sime Armoyan sold 91,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.75, for a total transaction of C$523,250.00.

Knight Therapeutics Stock Up 1.2 %

TSE:GUD traded up C$0.07 on Monday, hitting C$5.77. 37,365 shares of the company’s stock were exchanged, compared to its average volume of 76,109. The firm has a 50-day moving average price of C$5.46 and a 200-day moving average price of C$5.22. The company has a debt-to-equity ratio of 9.25, a current ratio of 3.20 and a quick ratio of 1.79. Knight Therapeutics Inc. has a 52 week low of C$4.35 and a 52 week high of C$5.95. The company has a market cap of C$583.75 million, a P/E ratio of -35.63, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.49.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings results on Thursday, March 21st. The company reported C($0.03) EPS for the quarter, missing the consensus estimate of C$0.02 by C($0.05). Knight Therapeutics had a negative return on equity of 2.14% and a negative net margin of 5.13%. The business had revenue of C$74.20 million for the quarter, compared to the consensus estimate of C$78.37 million. As a group, analysts expect that Knight Therapeutics Inc. will post 0.0202158 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GUD has been the topic of a number of recent analyst reports. Royal Bank of Canada lifted their price target on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the stock an “outperform” rating in a research report on Friday, March 22nd. Raymond James lifted their price target on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an “outperform” rating in a research report on Wednesday, March 6th.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.